Relationship between the expression of ARHGAP25 and RhoA in non-small cell lung cancer and vasculogenic mimicry

BMC Pulmonary Medicine

Table 2 The correlation between ARHGAP25, or RhoA, or VM and clinicopathological characteristics in NSCLC tissues

Variables	ARHGAP25			RhoA			VM
Variables	Negative	Positive	P	Negative	Positive	P	Negative	Positive	P
Age (years)			0.566			0.588			0.474
< 60	31	26		20	37		34	23
≥ 60	36	37		29	44		48	25
Gender			0.314			0.246			0.521
Female	15	19		10	24		23	11
Male	52	44		39	57		59	37
Smoking			0.155			0.391			0.063
No	31	37		28	40		48	20
Yes	36	26		21	41		34	28
Tumor size (cm)			0.015			0.055			0.016
≤ 3	19	31		24	26		38	12
> 3	48	32		25	55		44	36
Gross type			0.417			0.518			0.533
Central	45	38		33	50		54	29
Peripheral	22	25		16	31		28	19
Histologic type			0.902			0.789			0.224
LUSC	39	36		29	46		44	31
LUAD	28	27		20	35		38	17
Grade			0.478			0.535			0.004
Well	8	8		4	12		16	0
Moderate	39	42		32	49		46	35
Poor	20	13		13	20		20	13
LNM			0.015			0.001			0.001
No	23	35		31	27		46	12
Yes	44	28		18	54		36	36
TNM stage			0.013			0.002			0.011
I	13	27		23	17		31	9
II	21	12		13	20		23	10
III	33	24		13	44		28	29

NSCLC, non-small cell lung cancer; ARHGAP25, Rho GTPase-activating protein 25; RhoA, Ras homolog family member A; VM, vasculogenic mimicry; TNM, tumor-node-metastasis; LNM, lymph node metastasis; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma

ISSN: 1471-2466